Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors (Q37177594)

18 August 2017

1 reference

title

Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors (English)

1 reference

18 August 2017

1

Kwok-Kin Wong

1 reference

18 August 2017

publication date

1 June 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

60 Suppl 2

1 reference

18 August 2017

page(s)

S10-8

1 reference

Single-molecule imaging of EGFR signalling on the surface of living cells

18 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Specificity within the EGF family/ErbB receptor family signaling network

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Multiple positive and negative regulators of signaling by the EGF-receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Epidermal growth factor-related peptides and their receptors in human malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

ERBB receptors and cancer: the complexity of targeted inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Gefitinib versus cetuximab in lung cancer: round one.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Increased epidermal growth factor receptor in multidrug-resistant human neuroblastoma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Why the epidermal growth factor receptor? The rationale for cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

EGFR targeting of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

ErbB-targeted therapeutic approaches in human cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Gefitinib (ZD1839) in Previously Treated Advanced Non-Small-Cell Lung Cancer: Experience from a Single Institution

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Differences in lung cancer risk between men and women: examination of the evidence.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Strategies to overcome resistance to targeted protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2808%2970100-4

7 January 2021

10.1016/S0169-5002(08)70100-4

Identifiers

DOI

1 reference

18 August 2017

1 reference